Chronic rhinitis (CR) presents with symptoms such as rhinorrhea, nasal congestion, itching, and sneezing. Epidemiological surveys indicate that roughly 10–40 % of the population experiences the condition, making it a common disorder.
CR is categorized according to the presence of a specific IgE response to causative allergens: allergic rhinitis (AR) when IgE‑mediated, and non‑allergic rhinitis (NAR) when such a response is absent.
The principal pharmacologic agents employed for both AR and NAR include antihistamines, intranasal corticosteroids, nasal decongestants, and leukotriene‑receptor antagonists.
Recherches & Rapports5 sept. 2026•1 min de lecture
Chronic Rhinitis: Prevalence, Classification, and Standard Therapies
Chronic rhinitis affects 10‑40% of people and is divided into allergic and non‑allergic types; treatment typically involves antihistamines, nasal steroids, decongestants, and leukotriene antagonists.
Compilé par l'équipe PharmaCountry · Source : KPA News
Sujets :#chronic rhinitis#allergic rhinitis#nonallergic rhinitis#antihistamines#nasal steroids#leukotriene antagonists
Évaluations
(0)
(0)
(0)
(0)
(0)
Plus d'articles
Voir tous les articlesRecherches & Rapports
Global Finished Dosage Manufacturing Landscape 2026
5 oct. 2026
Actualités réglementairesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept. 2026
AnalysePharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept. 2026
Laissez votre note